2026-06-03
Introduction：The trigeminal nerve — the fifth cranial nerve — is the primary sensory and motor nerve of the face, comprising three branches: the ophthalmic, maxillary, and mandibular divisions. Trigeminal schwannomas arise from the Schwann cells of the nerve sheath and are benign tumors, accounting for 0.8–1.3% of all intracranial tumors. According to 2024 neurosurgical data, the tumor predominantly affects individuals between the ages of 40 and 60, with a slight female predominance. Approximately 70% of tumors are located in the posterior cranial fossa, 25% in the middle cranial fossa, and 5% span both fossae.
I. Overview
(I) Tumor Growth Characteristics
The tumor grows along the course of the trigeminal nerve, compressing nerve branches in the early stages and, as it enlarges, potentially invading surrounding structures such as the cavernous sinus and brainstem. Microscopically, two histological patterns are seen: Antoni A, characterized by densely packed cells, and Antoni B, characterized by loosely arranged cells with stromal edema. This structural heterogeneity accounts for the variable tissue consistency of these tumors and the corresponding variation in surgical difficulty.
II. Initial Presentation: Facial Sensory Disturbance
(I) Facial Numbness and Tingling
1. Symptom Characteristics
Facial numbness is the presenting symptom in 80–85% of patients, typically manifesting as persistent unilateral numbness with a sensation likened to wearing a mask. The distribution of numbness corresponds to the nerve branch under compression:
Ophthalmic branch involvement: Numbness of the forehead and periorbital region
Maxillary branch involvement: Numbness of the sides of the nose and cheek
Mandibular branch involvement: Numbness of the lower jaw and anterior two-thirds of the tongue
Case reviews indicate that in approximately 60% of patients, numbness begins in one region and gradually spreads to involve the entire ipsilateral half of the face as the tumor grows.
2. Mechanism
Tumor compression of the sensory root of the trigeminal nerve disrupts nerve conduction. Early changes consist of demyelination; in later stages, axonal degeneration may occur. Imaging demonstrates intimate contact between the tumor and the nerve root; on MRI T2-weighted sequences, the tumor appears hyperintense, forming a clear contrast against the hypointense nerve.
(II) Electric Shock-Like Pain
1. Pain Characteristics
Approximately 30–40% of patients develop electric shock-like pain resembling trigeminal neuralgia — severe, with sudden onset and sudden cessation, lasting seconds to minutes, and potentially triggered by speaking, chewing, or washing the face. Unlike primary trigeminal neuralgia, this pain is frequently accompanied by sensory loss and responds poorly to medication.
2. Clinical Case
A 2024 report in the Chinese Journal of Neurosurgery described a 52-year-old female patient who presented with recurrent electric shock-like pain in the right cheek. She was initially misdiagnosed with primary trigeminal neuralgia; pharmacological treatment was ineffective. Further investigation identified a trigeminal schwannoma in the cerebellopontine angle, and the pain resolved completely following surgery.
III. Hallmark Presentation: Difficulty Chewing and Opening the Mouth
(I) Masticatory Weakness and Muscle Atrophy
1. Symptom Characteristics
When the motor fibers of the mandibular branch are involved, patients develop weakness of the chewing muscles, manifesting as reduced bite force and difficulty eating hard foods. Symmetric atrophy of the temporalis and masseter muscles is observable in approximately 50% of patients, with palpably reduced muscle tone and jaw deviation toward the affected side on mouth opening.
2. Assessment Methods
Bite force is commonly assessed clinically using articulating paper — the bite impression on the affected side is typically shallower or absent. Electromyography demonstrates reduced compound muscle action potential (CMAP) amplitude and slowed nerve conduction velocity in the masticatory muscles.
(II) Restricted Mouth Opening
When the tumor involves the motor root of the trigeminal nerve or the muscular branches supplying the masticatory muscles, approximately 20–25% of patients develop restricted mouth opening. In severe cases, the interincisal distance falls below 3 cm, impairing eating and oral hygiene. CT may reveal fatty infiltration of the medial and lateral pterygoid muscles, indicating denervation.
IV. Symptoms from Involvement of Adjacent Cranial Nerves
(I) Hearing Loss and Balance Disturbance
When the tumor extends into the posterior cranial fossa and compresses the cochlear nerve, approximately 15–20% of patients develop tinnitus and hearing loss, occasionally accompanied by vertigo. Audiological testing reveals sensorineural hearing loss; vestibular function testing demonstrates reduced response on the affected side.
(II) Diplopia and Extraocular Movement Restriction
When the tumor extends superiorly into the cavernous sinus and compresses the oculomotor, trochlear, or abducens nerve, approximately 10% of patients develop diplopia with restricted eye movement in one or more directions. On examination, abnormal globe positioning may be noted — such as failure to abduct or difficulty with upgaze.
(III) Dysphagia and Aspiration
In rare instances, inferior extension of the tumor compresses the glossopharyngeal and vagus nerves; approximately 5% of patients develop dysphagia and aspiration with liquids, findings that must be distinguished from brainstem pathology. Laryngoscopy may reveal reduced vocal cord mobility on the affected side.
V. Symptoms of Raised Intracranial Pressure
(I) Headache and Vomiting
When the tumor reaches a substantial size (diameter exceeding 3 cm), approximately 25–30% of patients develop headache — typically a persistent dull ache in the occipital region or throughout the head — accompanied by nausea and vomiting. Vomiting may be projectile in character, related to tumor compression of the fourth ventricle or cerebral aqueduct causing hydrocephalus; MRI demonstrates ventricular system dilation.
(II) Impaired Consciousness
In rare cases, acute intratumoral hemorrhage or worsening obstructive hydrocephalus may cause confusion, somnolence, or even coma. This constitutes a neurological emergency; without prompt intervention, the condition may be life-threatening.
VI. Symptom Progression
(I) Characteristically Slow Progression
Trigeminal schwannomas are benign and symptoms progress slowly. The average interval from initial symptom onset to confirmed diagnosis is 1–3 years. Follow-up data from Peking Union Medical College Hospital indicate an annual tumor growth rate of approximately 0.5–1.0 cm, with a volume-doubling time of roughly 2–3 years.
(II) Factors Precipitating Sudden Deterioration
Cystic degeneration, intratumoral hemorrhage, or secondary infection can cause abrupt symptom worsening. Approximately 10% of patients experience acute facial pain and neurological deterioration due to intratumoral hemorrhage — a presentation that must be distinguished from cerebrovascular disease.
Frequently Asked Questions
1. What are the symptoms of trigeminal schwannoma?
The principal symptoms include:
Facial numbness or tingling, typically unilateral and distributed according to the involved nerve branch
Electric shock-like pain resembling trigeminal neuralgia but responding poorly to medication
Masticatory muscle weakness and atrophy, with restricted mouth opening
Possible accompanying hearing loss, diplopia, headache, and vomiting
The onset of any of the above symptoms warrants prompt cranial MRI.
2. How serious is trigeminal schwannoma?
Although benign, the consequences can be significant:
Neurological injury: Sustained compression can cause permanent facial sensory loss and masticatory dysfunction, substantially affecting quality of life.
Mass effect: Larger tumors can cause hydrocephalus and impaired consciousness, and may become life-threatening.
Misdiagnosis risk: Symptoms are easily confused with primary trigeminal neuralgia, leading to treatment delay.
Early diagnosis and surgical intervention are the keys to improving prognosis.
